FDA staff unconvinced by Sarepta's DMD drug, shares tank

(Reuters) - U.S. Food and Drug Administration staff said on Friday Sarepta Therapeutics Inc did not provide enough evidence to support the effectiveness of its drug to treat a rare muscle wasting disorder.

http://ift.tt/1le1u8h

from Reuters: Health News
via animenewspro